<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0038">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Sax</surname>
    <given-names>P. E.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Pozniak</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Montes</surname>
    <given-names>M. L.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Koenig</surname>
    <given-names>E.</given-names>
   </name>, 
   <name name-style="western">
    <surname>DeJesus</surname>
    <given-names>E.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Stellbrink</surname>
    <given-names>H.-J.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Antinori</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Workowski</surname>
    <given-names>K.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Slim</surname>
    <given-names>J.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Reynes</surname>
    <given-names>J.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Garner</surname>
    <given-names>W.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Custodio</surname>
    <given-names>J.</given-names>
   </name>, 
   <name name-style="western">
    <surname>White</surname>
    <given-names>K.</given-names>
   </name>, 
   <name name-style="western">
    <surname>SenGupta</surname>
    <given-names>D.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Cheng</surname>
    <given-names>A.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Quirk</surname>
    <given-names>E.</given-names>
   </name>
  </person-group> (
  <year>2017</year>). 
  <article-title>Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial</article-title>. 
  <source>
   <italic>The Lancet</italic>
  </source>, 
  <volume>390</volume>(
  <issue>10107</issue>), 
  <fpage>2073</fpage>–
  <lpage>2082</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32340-1</pub-id>
 </mixed-citation>
</ref>
